---
document_datetime: 2024-09-10 11:34:04
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/imvanex-epar-all-authorised-presentations_en.pdf
document_name: imvanex-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.917223
conversion_datetime: 2025-12-28 13:26:58.317309
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form      | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|-------------------|------------|--------------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/13/855/001  | IMVANEX           | --¹        | Suspension for injection | Subcutaneous use          | vial (glass)          | 0.5 ml                    | 20 vials    |
| EU/1/13/855/002  | IMVANEX           | --¹        | Suspension for injection | Subcutaneous use          | vial (glass)          | 0.5 ml                    | 1 vial      |
| EU/1/13/855/003  | IMVANEX           | --¹        | Suspension for injection | Subcutaneous use          | vial (glass)          | 0.5 ml                    | 10 vials    |

- --¹ Virus titer no less than of 5 x 10⁷ Inf.U

One dose (0.5 ml) contains:

Modified Vaccinia Ankara - Bavarian Nordic Live virus no less than 5 x 10⁷ Inf.U * *infectious units Produced in chick embryo cells